Tonogold Posts Presentation Detailing the JAG Minerals Acquisition
Highlights
TONOGOLD highlights the historic, low risk districts of uranium and vanadium production close to existing mineral production and processing.
The Company will seek to accelerate the exploration, development and production of these critically important minerals.
WOODLAND HILLS, CA / ACCESSWIRE / October 3, 2024 / TONOGOLD Resources Inc. (OTC PINK:TNGL) ("TONOGOLD" or the "Company") is pleased to inform shareholders that it has posted a presentation on its website detailing the previously announced acquisition of JAG Minerals Pty Ltd. This acquisition is the culmination of 12 months of work by both the TONOGOLD and JAG teams and, TONOGOLD believes, will lead to a leader in the uranium industry.
The presentation can be accessed via this link: https://tonogold.com/corporate/presentation/
TONOGOLD CEO William Hunter stated: "We're pleased to be moving this transaction forward and look forward to operating these assets upon closing. The strategic importance of nuclear power in an increasingly electrified economy makes the assets uniquely attractive and we are very optimistic about the future of Uranium American Resources going forward."
Enquiries
For further information, please contact:
William Hunter
Interim CEO Tonogold Resources Inc
M: +1 203 856 7285
E: bhunter@tonogold.com
SOURCE: Tonogold Resources, Inc.
View the original press release on accesswire.com
Tonogold Resources, Inc.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release
IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
Atha Energy Identifies Numerous Outcrops Hosting High-Grade Uranium Mineralization5.12.2024 07:00:00 CET | Press release
HIGHLIGHTS Surficial mapping was conducted as part of the 2024 Angilak Exploration Program that focused on areas strictly proximal to the Lac 50 Deposit and achieved its objective of discovering high-grade uranium mineralization on surface beyond the extents of the Lac 50 Deposit's Exploration Target Model; High-grade surficial uranium mineralization was identified between Lac 48, Lac 50, Lac 52, and Lac 54 trends, collectively known as the Lac 50 Deposit, along prospective new parallel trends; Discovery of outlined outcrops containing high-grade uranium mineralization along strike from the Lac 50 Deposit provide basis for future exploration and significantly de-risk expansion efforts; A zone of extensive bedrock outcrop with radioactivity up to >60,000 counts per second (cps) - >10,000 cps is indicative of high-grade uranium mineralization - was identified over a 3-kilometre strike length. The new discovery is located between the Mushroom Lake zone on the Lac 52 trend and the Hot zone
TACACS.net: Strengthening Network Security with Native Active Directory Integration4.12.2024 16:55:00 CET | Press release
The Weakest Link in Cybersecurity: Addressing Authentication Vulnerabilities SAN JOSE, CA / ACCESSWIRE / December 4, 2024 / In an era where 75% of security breaches are attributed to weak authentication, the importance of robust cybersecurity measures has never been greater. Recognizing this critical need, TACACS.net has emerged as the #1 choice for Active Directory (AD) integration, offering unmatched reliability, performance, and security. Authentication is often the weakest link in network security. If a hacker cannot authenticate to a device, they cannot exploit it. TACACS.net addresses this vulnerability by delivering a solution built to meet the needs of modern organizations, ensuring fast, secure, and seamless integration with existing infrastructure. Why TACACS.net Stands Out Most organizations rely on Active Directory to manage users, but competing solutions depend on middleware-complex intermediaries that often fail, usually at the worst possible time. TACACS.net is the only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom